Comparative Pharmacology
Head-to-head clinical analysis: FUROXONE versus PENTAMIDINE ISETHIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROXONE versus PENTAMIDINE ISETHIONATE.
FUROXONE vs PENTAMIDINE ISETHIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
Pentamidine isethionate is a synthetic aromatic diamidine that interferes with protozoal DNA replication, transcription, and RNA processing. Its exact mechanism is unclear but may involve inhibition of dihydrofolate reductase, interference with polyamine synthesis, and binding to kinetoplast DNA.
100 mg orally four times daily
Treatment of Pneumocystis jirovecii pneumonia (PCP): 4 mg/kg IV once daily for 21 days. Chemoprophylaxis of PCP: 300 mg inhalation via nebulizer every 4 weeks, or 4 mg/kg IV every 2-4 weeks. Treatment of leishmaniasis: 2-4 mg/kg IM or IV once daily or every other day for 14-30 doses.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Terminal elimination half-life is 18-24 hours in patients with normal renal function; prolongs to >48 hours in renal impairment, necessitating dose adjustment.
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Renal excretion accounts for approximately 60-70% of elimination, primarily as unchanged drug. Biliary/fecal elimination constitutes 10-20%, with the remainder undergoing metabolic clearance.
Category C
Category A/B
Antibacterial/Antiprotozoal
Antiprotozoal